Grant: Master's Award: Canada Graduate Scholarships
McGill University
$17,500.00
Biologic Therapy for Treatment of Rheumatoid Arthritis in Québec
EF 2009-10
Résumé
Since 2002, new and relatively costly medications known as 'biologic' therapies have been introduced in Québec for the treatment of autoimmune diseases. These include anti-Tumor Necrosis Factor (TNF) drugs, currently being used for the treatment of rheumatoid arthritis (RA), a disease that affects up to 1% of the population. RA is caused by an overly-active immune system that results in joint inflammation and destruction. Without aggressive treatment, severe damage occurs early, resulting in disability. RA has been traditionally treated with disease-modifying agents (DMARDs) to reduce joint damage, but with the advent of biologic therapies, like anti-TNF agents, more treatments options are now available. As anti-TNF drugs are more expensive than traditional DMARDs, determining the cost:benefit ratios of these agents are important to help in treatment decisions. The goal of the project is to profile the use of anti-TNF drugs from the time of their introduction, in a population-based sample, assessing changes in prescription of these agents across regions and time. The project will also examine potential differences in the use of these agents according to physician and patient characteristics.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
200335
Name
Ng Ryan
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Musculoskeletal Health and Arthritis
Theme2
Health systems / services
Prcname2
Canada Graduate Scholarships Master's Awards A
Projecttitle
Biologic Therapy for Treatment of Rheumatoid Arthritis in Québec
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Administrative Data; Biologic Therapies; Clinical Epidemiology; Cohort Study; Epidemiology; Health Economics; Health Service Use; Rheumatic Diseases; Rheumatoid Arthritis; Rheumatology
Abstract
Since 2002, new and relatively costly medications known as 'biologic' therapies have been introduced in Québec for the treatment of autoimmune diseases. These include anti-Tumor Necrosis Factor (TNF) drugs, currently being used for the treatment of rheumatoid arthritis (RA), a disease that affects up to 1% of the population. RA is caused by an overly-active immune system that results in joint inflammation and destruction. Without aggressive treatment, severe damage occurs early, resulting in disability. RA has been traditionally treated with disease-modifying agents (DMARDs) to reduce joint damage, but with the advent of biologic therapies, like anti-TNF agents, more treatments options are now available. As anti-TNF drugs are more expensive than traditional DMARDs, determining the cost:benefit ratios of these agents are important to help in treatment decisions. The goal of the project is to profile the use of anti-TNF drugs from the time of their introduction, in a population-based sample, assessing changes in prescription of these agents across regions and time. The project will also examine potential differences in the use of these agents according to physician and patient characteristics.
Competitiondate
201002
Approvedterm2
1 yr 0 mth
Pinamesdelim
Ng, Ryan
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~